Their value comes from retaining tumor-associated genetic diversity, cellular heterogeneity, and tumor-specific behavior that may be reduced in established cell lines. These features allow researchers to examine cancer as a varied cell population rather than as a uniform model. Consequently, experiments can provide biologically relevant evidence about disease mechanisms and treatment responses.
Cellular heterogeneity means that the cultured population can contain cells with different biological characteristics and treatment sensitivities. This diversity may reveal varied responses within the same tumor-derived sample, but it also complicates interpretation because results may not represent every cell equally. Researchers must therefore consider population variability when evaluating mechanisms or drug effects.
Primary cancer cells preserve features closer to the original tumor, including genetic diversity and tumor-specific behavior, whereas established cell lines may provide a more uniform experimental system. As a result, the two models can show different responses to treatment. Comparing them can help identify findings that depend on tumor biology rather than on a simplified culture model.
Researchers begin with tumor tissue obtained from a patient or animal model, then dissociate the sample to release individual cells or a cell population. The resulting material is placed under controlled culture conditions selected to support survival. This workflow creates a usable experimental population while attempting to preserve relevant tumor characteristics during maintenance.
Primary cancer cells can have limited growth and demanding culture requirements, making them more difficult to maintain than simpler experimental systems. Samples may also vary substantially from one source to another, which can affect reproducibility and comparisons. These constraints require careful interpretation of results and recognition that a single sample may not capture the full range of tumor behavior.
They are particularly useful when researchers need to investigate disease mechanisms, treatment responses, or resistance in a system that more closely reflects tumor biology. Their tumor-derived characteristics also support studies of interactions with the tumor microenvironment. Although culture challenges remain, this relevance can strengthen the interpretation of preclinical findings beyond what established cell lines alone may provide.